Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hair loss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.
The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.
The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.
The conversation is about someone considering adding topical Cetirizine 1% to their existing hair loss treatment regimen and seeking advice on where to buy it and others' experiences with it.
The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The conversation is about finding a legitimate source for Procyanidin B2 or Apple Extract with a clear percentage of Procyanidin B2 for making a topical solution. The user reports thicker and darker body hair after taking Oral Apple Polyphenols extract.
Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.
Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.
The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
The conversation discusses the hair loss treatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.
The conversation is about using GHK-Cu, a copper peptide, for hair loss treatment. Users discuss their experiences, dosages, and additional benefits like improved skin and energy.
Amino acids, particularly Cysteine, are important for hair growth and may be lacking in a normal diet. Using a protein powder that includes these amino acids can help improve hair growth and strength.
A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
CB-03-01, also known as Breezula, is being considered as an alternative to DHT blockers for hair loss. Users are discussing its effectiveness, potential regrowth, side effects like scalp irritation, and hormonal impacts.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
The conversation discusses the use of peptides C60 and GHK-Cu for hair growth. Participants are sharing their experiences or knowledge about these treatments.
The conversation discusses the lack of clinical studies on cysteine alone for hair loss, with the original poster already using medications like Minoxidil and finasteride. Suggestions include trying 2ddr as a growth stimulant, though concerns about side effects like gas are mentioned.